Key result
Compared with white men, black and Hispanic women had a 30% to 36% lower likelihood of being adherent to evidence-based preventive therapies at 12 months after acute myocardial infarction (P<0.05).
Why the study?
Are there racial/ethnic and gender gaps in the use of and adherence to β-blockers, ACEi/ARBs, and statins among elderly Medicare beneficiaries after acute myocardial infarction?
Population
85,017 Medicare beneficiaries ≥65 years of age who were alive 30 days after an index acute myocardial…
Comparison
Evidence-based preventive therapies vs Comparison across race/ethnicity and gender
Design
Cohort
Follow-up
12 months
Authors
Loading...
Adherence gaps in minority women should not yet change practice; leaves open drivers and equity interventions in elderly post-MI patients.
Cohort (n=85,017)
Are there racial/ethnic and gender gaps in the use of and adherence to β-blockers, ACEi/ARBs, and statins among elderly Medicare beneficiaries after acute myocardial infarction?
Effect estimate: 30%-36% lower likelihood
p-value: p=<0.05
Significant racial, ethnic, and gender disparities exist in long-term adherence to evidence-based therapies after acute myocardial infarction among elderly Medicare beneficiaries.
Lauffenburger et al. (2013) conducted a cohort in Acute myocardial infarction (n=85,017). Evidence-based preventive therapies (β-blockers, ACE inhibitors/ARBs, and statins) vs. White men was evaluated on Patient adherence to therapies at 12 months after discharge (30%-36% lower likelihood, p=<0.05). Compared with white men, black and Hispanic women had a 30% to 36% lower likelihood of being adherent to evidence-based preventive therapies at 12 months after acute myocardial infarction (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: